BRPI0908406A2 - Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes - Google Patents
Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetesInfo
- Publication number
- BRPI0908406A2 BRPI0908406A2 BRPI0908406-1A BRPI0908406A BRPI0908406A2 BR PI0908406 A2 BRPI0908406 A2 BR PI0908406A2 BR PI0908406 A BRPI0908406 A BR PI0908406A BR PI0908406 A2 BRPI0908406 A2 BR PI0908406A2
- Authority
- BR
- Brazil
- Prior art keywords
- stimulants
- methods
- insulin secretion
- treat diabetes
- quinoxalinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08004053 | 2008-03-05 | ||
| EP08004053.8 | 2008-03-05 | ||
| PCT/EP2009/000209 WO2009109258A1 (en) | 2008-03-05 | 2009-01-15 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0908406A2 true BRPI0908406A2 (pt) | 2015-08-11 |
| BRPI0908406B1 BRPI0908406B1 (pt) | 2019-04-09 |
| BRPI0908406B8 BRPI0908406B8 (pt) | 2023-02-07 |
Family
ID=40547943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908406A BRPI0908406B8 (pt) | 2008-03-05 | 2009-01-15 | Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8415352B2 (pt) |
| EP (1) | EP2247580B1 (pt) |
| JP (1) | JP5618837B2 (pt) |
| KR (1) | KR101637387B1 (pt) |
| CN (1) | CN101952258B (pt) |
| AR (1) | AR070797A1 (pt) |
| AU (1) | AU2009221327B2 (pt) |
| BR (1) | BRPI0908406B8 (pt) |
| CA (1) | CA2717718C (pt) |
| DK (1) | DK2247580T3 (pt) |
| EA (1) | EA021904B1 (pt) |
| ES (1) | ES2548583T3 (pt) |
| HU (1) | HUE027811T2 (pt) |
| IL (1) | IL207720A (pt) |
| MX (1) | MX2010009576A (pt) |
| PT (1) | PT2247580E (pt) |
| WO (1) | WO2009109258A1 (pt) |
| ZA (1) | ZA201007059B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
| LT2970218T (lt) | 2013-03-12 | 2019-03-12 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitoriai |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| CN104628661A (zh) * | 2015-02-05 | 2015-05-20 | 北京理工大学 | 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途 |
| JP6938510B2 (ja) | 2015-12-24 | 2021-09-22 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｃｆｔｒ制御因子及びこの使用方法 |
| RU2742934C2 (ru) | 2015-12-24 | 2021-02-11 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Кфтр регуляторы и способы их применения |
| JP6938509B2 (ja) | 2015-12-24 | 2021-09-22 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｃｆｔｒ制御因子及びこの使用方法 |
| CN105769870A (zh) * | 2016-04-09 | 2016-07-20 | 李曼 | 一种治疗糖尿病的药物 |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| JP2020531511A (ja) | 2017-08-24 | 2020-11-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 眼球用医薬組成物 |
| CN109793739A (zh) * | 2019-01-14 | 2019-05-24 | 北京理工大学 | 一种喹喔啉酮衍生物的结构、制备方法及用途 |
| CN109796417A (zh) * | 2019-01-14 | 2019-05-24 | 北京理工大学 | 一系列喹喔啉酮衍生物的结构、制备方法及用途 |
| CN114907323B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 喹喔啉酮类化合物及其制备方法和应用 |
| CN114957222B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 化合物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU410015A1 (pt) * | 1971-06-22 | 1974-01-05 | ||
| SU616955A1 (ru) * | 1977-03-02 | 2006-12-27 | Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького | 2-(α-бромфенацил)-хиноксалон-3, проявляющий противовоспалительную активность |
| US4181724A (en) * | 1978-09-11 | 1980-01-01 | The Upjohn Company | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals |
| FR2653430B1 (fr) | 1989-10-23 | 1991-12-20 | Pf Medicament | Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique. |
| EP0995742A4 (en) | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
| WO1999011632A1 (fr) * | 1997-09-01 | 1999-03-11 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide quinoxalinecarboxylique disubstitues en position 6,7-asymetrique, sels d'addition de ces derives, et procedes de preparation de ces derives et de ces sels |
| BR9815785A (pt) * | 1998-03-31 | 2000-12-05 | Warner Lambert Co | Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina |
| DE10343098A1 (de) * | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
| JP2007517800A (ja) * | 2004-01-06 | 2007-07-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての（３−オキソ−３，４−ジヒドロ−キノキサリン−２−イル−アミノ）−ベンズアミド誘導体および関連化合物 |
| DE102004023332A1 (de) * | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2007135527A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
-
2009
- 2009-01-15 EP EP09718118.4A patent/EP2247580B1/en active Active
- 2009-01-15 MX MX2010009576A patent/MX2010009576A/es active IP Right Grant
- 2009-01-15 AU AU2009221327A patent/AU2009221327B2/en active Active
- 2009-01-15 CA CA2717718A patent/CA2717718C/en active Active
- 2009-01-15 WO PCT/EP2009/000209 patent/WO2009109258A1/en active Application Filing
- 2009-01-15 BR BRPI0908406A patent/BRPI0908406B8/pt active IP Right Grant
- 2009-01-15 KR KR1020107022236A patent/KR101637387B1/ko active IP Right Grant
- 2009-01-15 EA EA201001407A patent/EA021904B1/ru not_active IP Right Cessation
- 2009-01-15 DK DK09718118.4T patent/DK2247580T3/en active
- 2009-01-15 CN CN200980105428.XA patent/CN101952258B/zh active Active
- 2009-01-15 ES ES09718118.4T patent/ES2548583T3/es active Active
- 2009-01-15 PT PT97181184T patent/PT2247580E/pt unknown
- 2009-01-15 US US12/920,736 patent/US8415352B2/en active Active
- 2009-01-15 HU HUE09718118A patent/HUE027811T2/en unknown
- 2009-01-15 JP JP2010549024A patent/JP5618837B2/ja active Active
- 2009-03-05 AR ARP090100781A patent/AR070797A1/es unknown
-
2010
- 2010-08-19 IL IL207720A patent/IL207720A/en active IP Right Grant
- 2010-10-04 ZA ZA2010/07059A patent/ZA201007059B/en unknown
-
2013
- 2013-01-04 US US13/734,288 patent/US8835634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA021904B1 (ru) | 2015-09-30 |
| EA201001407A1 (ru) | 2011-06-30 |
| DK2247580T3 (en) | 2015-10-05 |
| HUE027811T2 (en) | 2016-11-28 |
| EP2247580B1 (en) | 2015-07-08 |
| ZA201007059B (en) | 2011-06-29 |
| CN101952258B (zh) | 2014-03-19 |
| WO2009109258A1 (en) | 2009-09-11 |
| MX2010009576A (es) | 2010-09-24 |
| CN101952258A (zh) | 2011-01-19 |
| CA2717718A1 (en) | 2009-09-11 |
| AU2009221327A1 (en) | 2009-09-11 |
| CA2717718C (en) | 2016-05-31 |
| JP5618837B2 (ja) | 2014-11-05 |
| US20130123257A1 (en) | 2013-05-16 |
| AR070797A1 (es) | 2010-05-05 |
| ES2548583T3 (es) | 2015-10-19 |
| US8415352B2 (en) | 2013-04-09 |
| EP2247580A1 (en) | 2010-11-10 |
| KR20100123899A (ko) | 2010-11-25 |
| BRPI0908406B1 (pt) | 2019-04-09 |
| IL207720A (en) | 2014-12-31 |
| US8835634B2 (en) | 2014-09-16 |
| IL207720A0 (en) | 2010-12-30 |
| JP2011513343A (ja) | 2011-04-28 |
| PT2247580E (pt) | 2015-10-19 |
| US20110015194A1 (en) | 2011-01-20 |
| AU2009221327B2 (en) | 2014-03-27 |
| KR101637387B1 (ko) | 2016-07-07 |
| BRPI0908406B8 (pt) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0908406A2 (pt) | Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes | |
| BRPI0921802A8 (pt) | uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. | |
| BRPI0921389A2 (pt) | seringa de um só uso, de inutilização automática | |
| FR2945534B1 (fr) | DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
| BRPI0910690A2 (pt) | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo [3,4-d]pirimidin-4-ona e uso dos mesmos como moduladores de pde9a | |
| BR112012000619A2 (pt) | seringa pré-preenchida incluindo um absorvedor de oxigênio | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| BRPI0908544A2 (pt) | derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes | |
| BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
| FR2933700B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| DOP2010000282A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
| BRPI0919812A2 (pt) | combinações de compostos antibacterianos heterocíclicos hirdrogenados com outros compostos antibacterianos e o uso dos mesmos como medicamentos | |
| BR112015002755A2 (pt) | derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados | |
| FR2953520B1 (fr) | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| BR112012027545A2 (pt) | composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo | |
| FR2952934B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| FR2943669B1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
| FR2954943B1 (fr) | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique | |
| BRPI0908569A2 (pt) | estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes | |
| FR2927625B1 (fr) | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique | |
| BRPI0923373A2 (pt) | Combinação de insulina com derivados de triazina e seu uso para tratar diabetes. | |
| WO2011158161A3 (en) | Process for making up or caring for keratin fibres using retractable fibres, and use thereof | |
| BR112012005102A2 (pt) | seringa de segurança descártavel com ponta de agulha retrátil | |
| BRPI0814999A2 (pt) | Derivados de bezoil-piperidina como moduladores duais dos receptores 5-ht2a e d3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (54) TITULO. |